Leap Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 54
- Market Cap
- $113.2M
- Website
- http://www.leaptx.com
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 2 Study of DKN-01 in Colorectal Cancer
- Conditions
- Colorectal CancerColo-rectal CancerColorectal Cancer MetastaticColorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT05480306
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists & Research Institute (FCS), Cape Coral, Florida, United States
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
- Conditions
- Esophageal NeoplasmAdenocarcinoma of the Gastroesophageal JunctionGastroEsophageal CancerSquamous Cell CarcinomaGastric AdenocarcinomaEndometrial CancerUterine CancerOvarian CancerCarcinosarcomaGastric Cancer
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Leap Therapeutics, Inc.
- Registration Number
- NCT04681248
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Cedars Sinai Medical Care Foundation, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
- Conditions
- Gastric AdenocarcinomaGastric CancerGastroEsophageal Cancer
- Interventions
- Drug: DKN-01 300mgDrug: DKN-01 600mgDrug: DKN-01 400mg
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT04363801
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
- Conditions
- Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast CancerAdvanced Metastatic Castration-Resistant Prostate CancerAdvanced Platinum-Resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03861403
- Locations
- 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
- Conditions
- Endometrial CancerUterine CancerOvarian CancerCarcinosarcoma
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03395080
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Florida Cancer Specialists & Research Institute, West Palm Beach, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Leap Therapeutics Halves Workforce and Refocuses Cancer Drug Development Amid Market Challenges
Leap Therapeutics has announced a significant restructuring, reducing its workforce by approximately 50% and narrowing the development focus of its lead cancer drug candidate in response to challenging market conditions.
Leap Therapeutics' FL-501 Shows Promise in Reversing Cancer Cachexia in Preclinical Studies
Leap Therapeutics' novel GDF-15 neutralizing antibody FL-501 demonstrated superior efficacy in preclinical models, fully restoring body composition and reversing key indicators of cancer cachexia.
Leap Therapeutics Reports Mixed Phase II Results for Sirexatamab in Gastrointestinal Cancers
Leap Therapeutics' anti-DKK1 antibody sirexatamab shows promising results in colorectal cancer trials while falling short in gastric cancer studies, leading to significant stock impact.
Sirexatamab Shows Promise in Colorectal Cancer, Fails to Meet Endpoints in Gastric Cancer
Leap Therapeutics' DeFianCe study showed a 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab, bevacizumab, and chemotherapy.
Leap Therapeutics Announces Enrollment Completion in Phase 2 DeFianCe Study and FL-501 Development
Leap Therapeutics completed enrollment in Part B of the Phase 2 DeFianCe study, evaluating DKN-01 with bevacizumab and chemotherapy for second-line advanced colorectal cancer, with data expected mid-2025.
DKN-01 Plus Tislelizumab and Chemotherapy Shows Promise in Advanced Gastric Cancer
A phase IIa trial of DKN-01 with tislelizumab and chemotherapy demonstrated a 73% objective response rate in advanced gastric or gastroesophageal junction adenocarcinoma.